KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $2.1 billion.

  • Sarepta Therapeutics' Total Non-Current Liabilities fell 834.01% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 834.01%. This contributed to the annual value of $2.4 billion for FY2024, which is 88.26% up from last year.
  • Sarepta Therapeutics' Total Non-Current Liabilities amounted to $2.1 billion in Q3 2025, which was down 834.01% from $2.3 billion recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Total Non-Current Liabilities ranged from a high of $2.7 billion in Q4 2022 and a low of $2.1 billion during Q3 2025
  • Over the past 5 years, Sarepta Therapeutics' median Total Non-Current Liabilities value was $2.3 billion (recorded in 2025), while the average stood at $2.3 billion.
  • As far as peak fluctuations go, Sarepta Therapeutics' Total Non-Current Liabilities soared by 2509.52% in 2022, and later plummeted by 1417.79% in 2023.
  • Sarepta Therapeutics' Total Non-Current Liabilities (Quarter) stood at $2.2 billion in 2021, then rose by 24.36% to $2.7 billion in 2022, then decreased by 12.54% to $2.4 billion in 2023, then grew by 0.88% to $2.4 billion in 2024, then dropped by 10.51% to $2.1 billion in 2025.
  • Its Total Non-Current Liabilities stands at $2.1 billion for Q3 2025, versus $2.3 billion for Q2 2025 and $2.3 billion for Q1 2025.